Drug Database
Back to search

Poland· PL-100053111

Pimafucin

A natamycin product containing natamycinum, registered in Poland by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 3 of our 19 countries.

ATC D01AA02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPimafucinATCD01AA02REGISTER NO.PL-100053111PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about natamycinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Natamycin is registered in 3 of 19 countries.

Countries holding a registration under ATC D01AA02 (natamycin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search natamycin products by name

Natamycin · ATC D01AA02

3 / 19 countries

  • Czechiaprice
  • Finlandprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Natamycinum
Manufacturer
CHEPLAPHARM Arzneimittel GmbH
Country
Poland (PL)
ATC code
D01AA02
ATC class
Natamycin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990191918
  • gtin
    05909990743681

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Natamycin in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All natamycin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Czechia · Pimafucin
  • Finland · Pimafucin
  • Hungary · Pimafucin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3e27d792-d3cb-48bb-9936-df90188e60f8
GET /v1/drugs/3e27d792-d3cb-48bb-9936-df90188e60f8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Globulki",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05909990191918 ¦ Rp ¦ 7972\n3 szt.\n05909990743681 ¦ Rp ¦ 54383\n6 szt.",
  "substance": "Natamycinum 100 mg",
  "common_name": "Natamycinum",
  "pl_product_id": "100053111",
  "pozwolenie_nr": "01919",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about natamycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console